Old API Wind-down Ltd.
Old API Wind-down Ltd. (ARLZ): 1 pipeline candidate · ~7 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
6.6 months
D/E -74.14 · 0% dilution
Lead: Approved
1 candidate
N/A
N/A
A transparent, data-derived signal for Old API Wind-down Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$43.9M
Quarterly Burn
$26.5M
Runway
6.6 mo
Revenue
$38.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| treximet | Approved |
Frequently asked questions
How many drug candidates are in Old API Wind-down Ltd.'s pipeline?
Old API Wind-down Ltd. (ARLZ) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Old API Wind-down Ltd.'s lead drug candidate?
Old API Wind-down Ltd.'s most advanced tracked candidate is treximet (Approved) for acute treatment of migraine attacks.
What is Old API Wind-down Ltd.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Old API Wind-down Ltd. has approximately 6.6 months of cash runway.
Who is the CEO of Old API Wind-down Ltd.?
Adrian Adams is the chief executive officer of Old API Wind-down Ltd. (ARLZ).
Get the full picture on Old API Wind-down Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.